203 related articles for article (PubMed ID: 31555486)
1. B7x-from bench to bedside.
Kaur G; Janakiram M
ESMO Open; 2019; 4(5):e000554. PubMed ID: 31555486
[TBL] [Abstract][Full Text] [Related]
2. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
[No Abstract] [Full Text] [Related]
3. The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial.
John P; Wei Y; Liu W; Du M; Guan F; Zang X
Trends Pharmacol Sci; 2019 Nov; 40(11):883-896. PubMed ID: 31677920
[TBL] [Abstract][Full Text] [Related]
4. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model.
Chand D; Dhawan D; Sankin A; Ren X; Lin J; Schoenberg M; Knapp DW; Zang X
Bladder Cancer; 2019 Jan; 5(1):63-71. PubMed ID: 30854414
[TBL] [Abstract][Full Text] [Related]
6. Structure and cancer immunotherapy of the B7 family member B7x.
Jeon H; Vigdorovich V; Garrett-Thomson SC; Janakiram M; Ramagopal UA; Abadi YM; Lee JS; Scandiuzzi L; Ohaegbulam KC; Chinai JM; Zhao R; Yao Y; Mao Y; Sparano JA; Almo SC; Zang X
Cell Rep; 2014 Nov; 9(3):1089-98. PubMed ID: 25437562
[TBL] [Abstract][Full Text] [Related]
7. B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors.
Yuan Z; Gardiner JC; Maggi EC; Huang S; Adem A; Bagdasarov S; Li G; Lee S; Slegowski D; Exarchakis A; Howe JR; Lattime EC; Zang X; Libutti SK
Endocr Relat Cancer; 2021 Feb; 28(2):135-149. PubMed ID: 33410766
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8
Li J; Lee Y; Li Y; Jiang Y; Lu H; Zang W; Zhao X; Liu L; Chen Y; Tan H; Yang Z; Zhang MQ; Mak TW; Ni L; Dong C
Immunity; 2018 Apr; 48(4):773-786.e5. PubMed ID: 29625896
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies.
Janakiram M; Pareek V; Cheng H; Narasimhulu DM; Zang X
Immunotherapy; 2016 Jun; 8(7):809-19. PubMed ID: 27349980
[TBL] [Abstract][Full Text] [Related]
10. Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells.
Ohaegbulam KC; Liu W; Jeon H; Almo SC; Zang X
Oncotarget; 2017 Oct; 8(47):82740-82753. PubMed ID: 29137299
[TBL] [Abstract][Full Text] [Related]
11. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
Bolandi N; Derakhshani A; Hemmat N; Baghbanzadeh A; Asadzadeh Z; Afrashteh Nour M; Brunetti O; Bernardini R; Silvestris N; Baradaran B
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639059
[TBL] [Abstract][Full Text] [Related]
12. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
Zang X; Thompson RH; Al-Ahmadie HA; Serio AM; Reuter VE; Eastham JA; Scardino PT; Sharma P; Allison JP
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19458-63. PubMed ID: 18042703
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways.
Wang F; Cali Daylan AE; Deng L; Yang J; Sharma J; Su C; Li S; Zang X; Halmos B; Borczuk A; Cheng H
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444481
[TBL] [Abstract][Full Text] [Related]
14. Generation and characterization of B7-H4/B7S1/B7x-deficient mice.
Suh WK; Wang S; Duncan GS; Miyazaki Y; Cates E; Walker T; Gajewska BU; Deenick E; Dawicki W; Okada H; Wakeham A; Itie A; Watts TH; Ohashi PS; Jordana M; Yoshida H; Mak TW
Mol Cell Biol; 2006 Sep; 26(17):6403-11. PubMed ID: 16914726
[TBL] [Abstract][Full Text] [Related]
15. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
[TBL] [Abstract][Full Text] [Related]
16. Host b7x promotes pulmonary metastasis of breast cancer.
Abadi YM; Jeon H; Ohaegbulam KC; Scandiuzzi L; Ghosh K; Hofmeyer KA; Lee JS; Ray A; Gravekamp C; Zang X
J Immunol; 2013 Apr; 190(7):3806-14. PubMed ID: 23455497
[TBL] [Abstract][Full Text] [Related]
17. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma.
Podojil JR; Glaser AP; Baker D; Courtois ET; Fantini D; Yu Y; Eaton V; Sivajothi S; Chiang M; Das A; McLaughlin KA; Robson P; Miller SD; Meeks JJ
Oncoimmunology; 2020; 9(1):1744897. PubMed ID: 32363111
[TBL] [Abstract][Full Text] [Related]
18. A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression.
Liu Y; John P; Nishitani K; Cui J; Nishimura CD; Christin JR; Couturier N; Ren X; Wei Y; Pulanco MC; Galbo PM; Zhang X; Fu W; Cui W; Bartholdy BA; Zheng D; Lauvau G; Fineberg SA; Oktay MH; Zang X; Guo W
Dev Cell; 2023 Dec; 58(23):2700-2717.e12. PubMed ID: 37963469
[TBL] [Abstract][Full Text] [Related]
19. V-set domain containing T-cell activation inhibitor-1 (VTCN1): A potential target for the treatment of autoimmune diseases.
Vaishnav J; Khan F; Yadav M; Parmar N; Buch H; Jadeja SD; Dwivedi M; Begum R
Immunobiology; 2022 Nov; 227(6):152274. PubMed ID: 36095871
[TBL] [Abstract][Full Text] [Related]
20. T cell coinhibition and immunotherapy in human breast cancer.
Janakiram M; Abadi YM; Sparano JA; Zang X
Discov Med; 2012 Oct; 14(77):229-36. PubMed ID: 23114578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
